A Phase 1 interventional study of VIS171 in Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA) and Immune-mediated Focal Segmental Glomerulosclerosis (FSGS), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Lupus Erythematosus, Systemic with a site in Romania — 14 open to participants now, 26 under way, 14 of them phase 3. Lupus Erythematosus, Systemic · Romania.
Among the 60 studies in Lupus Erythematosus, Systemic with a site in Romania, this one is the 55th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 4 of the 25 other live ones, and was the 51st registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →14 of the 60 studies in Lupus Erythematosus, Systemic with a site in Romania are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Romania, United States, Argentina and 32 more countries
Ages 5–80
Stefan Lujinschi · Sites in Romania
Ages 18+
Boehringer Ingelheim · Sites in Romania, United States, Argentina and 18 more countries
Ages 18–74
EMD Serono Research & Development Institute, Inc. · Sites in Romania, United States, Australia and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in Romania, United States, Australia and 17 more countries
Ages 18–75
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 22 · Phase 3 28 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 408 across the 59 interventional studies, 100 across the 1 observational. Of the 34 that completed or were terminated, 28 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 2 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
6 of the studies in Lupus Erythematosus, Systemic with a site in Romania that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT05624749Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | 2027-04-12 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06613360Cullinan Therapeutics Inc.A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
Add all 6 to your calendar (.ics) → With an account.
Among the 60 studies in Lupus Erythematosus, Systemic with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Estimated (eGFR) >30 milliliters/minute/1.73 square meters (mL/min/1.73 m\^2) at the screening visit.
For SLE participants:
Participant has a confirmed diagnosis of SLE according to European League Against Rheumatism/American College of Rheumatology SLE classification criteria ≥ 24 weeks prior to signing the form (ICF).
For AA participants:
Current episode of AA is of duration > 24 weeks (without evidence of spontaneous terminal hair regrowth at the time of screening and first treatment, i.e., no more than 10% regrowth), but ≤ 5 years from onset of current episode of severe scalp hair loss.
For FSGS participants:
Exclusion Criteria:
Note: Other protocol-specified Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive VIS171 dose via SC injection, from Week 1 to Week 21.
Drug: VIS171
VIS171 will be administered as a SC injection.
Number of Participants with Treatment Emergent Adverse Events (TEAEs) Graded by Severity
Time frame: From first dose of the study drug up to end of the study (up to Week 45)
Change from Baseline in Absolute Number of Regulatory T (Treg) Cells, Total T Helper Cells, Cytotoxic T Cells, and Natural Killer Cells in Blood
Time frame: From baseline up to Week 21
Percent Change from Baseline in Treg Cells/CD4+ Cells, Total T Helper Cells, Cytotoxic T Cells, and Natural Killer Cells in Blood
Time frame: From baseline up to Week 21
Serum Concentration of VIS171 Over Time
Time frame: Up to Week 21
Number of Participants with Confirmed Positive or Negative Anti-drug Antibody (ADA) Titers
Time frame: Up to Week 21
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets,or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 19 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
Otsuka Pharmaceutical Development & Commercialization, Inc. →